Journal of Medicinal Chemistry p. 10644 - 10651 (2012)
Update date:2022-08-03
Topics:
Luo, Guanglin
Chen, Ling
Conway, Charles M.
Denton, Rex
Keavy, Deborah
Signor, Laura
Kostich, Walter
Lentz, Kimberley A.
Santone, Kenneth S.
Schartman, Richard
Browning, Marc
Tong, Gary
Houston, John G.
Dubowchik, Gene M.
MacOr, John E.
Calcitonin gene-related peptide (CGRP) receptor antagonists have demonstrated clinical efficacy in the treatment of acute migraine. Herein, we describe the design, synthesis, and preclinical characterization of a highly potent, oral CGRP receptor antagonist BMS-927711 (8). Compound 8 has good oral bioavailability in rat and cynomolgus monkey, attractive overall preclinical properties, and shows dose-dependent activity in a primate model of CGRP-induced facial blood flow. Compound 8 is presently in phase II clinical trials.
View MoreNanJing Rate Biochemicals CO., LTD
Contact:+86-25-84931986
Address:NO. 1 Hongjing Road,Jiangning Science Park,Nanjing,China
Huaihua Baohua Biotechnology Co.,Ltd
website:http://www.baochengchem.com
Contact:86-519-82698291
Address:HouYang chemical development zone,Jintan,Jiangsu,China (213200)
Contact:+86-21-61318535
Address:Building 29,No.2139 Xizha Road, Fengxian District, Shanghai
NEW FORTUNE INDUSTRIAL CO.,LTD.
website:http://newfortune.lookchem.com/
Contact:+86-25-8645-9456
Address:C4-105 GREEN ISLAND FLOWER TOWN
Shanxi Tongji Pharmaceuticals Co., Ltd.
Contact:+86-359-3024784
Address:Xikuang South Road, Ruicheng County , Shanxi
Doi:10.1016/j.tet.2015.02.032
(2015)Doi:10.1002/cbic.201100522
(2012)Doi:10.1021/ja00016a072
(1991)Doi:10.1039/P19910001139
(1991)Doi:10.1016/j.poly.2011.11.013
(2012)Doi:10.1016/j.ejmech.2020.112785
(2020)